Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$734M |
| 2 |
Adobe
ADBE
|
+$488M |
| 3 |
Merck
MRK
|
+$443M |
| 4 |
Tesla
TSLA
|
+$366M |
| 5 |
AGN
Allergan plc
AGN
|
+$315M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$682M |
| 2 |
Perrigo
PRGO
|
+$585M |
| 3 |
Gilead Sciences
GILD
|
+$556M |
| 4 |
EMC
EMC CORPORATION
EMC
|
+$432M |
| 5 |
Morgan Stanley
MS
|
+$401M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.94% |
| 2 | Consumer Discretionary | 14.99% |
| 3 | Communication Services | 11.27% |
| 4 | Technology | 9.94% |
| 5 | Financials | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SDRL
526
DELISTED
Seadrill Limited Common Stock
SDRL
| $3.31M | ﹤0.01% |
301
+173
| +135% | +$2.04M |
|
527
Archer Daniels Midland
ADM
$38.7B
| $3.3M | ﹤0.01% |
76,070
-12,622
| -14% | -$510K |
|
528
DexCom
DXCM
$29B
| $3.25M | ﹤0.01% |
366,960
-56,772
| -13% | -$449K |
|
529
Amgen
AMGN
$209B
| $3.22M | ﹤0.01% |
28,179
-284,144
| -91% | -$32.3M |
|
|
NAK
530
Northern Dynasty Minerals
NAK
$773M
| $3.14M | ﹤0.01% |
2,454,438
| – | – |
|
531
Southwest Airlines
LUV
$21.7B
| $3.13M | ﹤0.01% |
165,878
-71,901
| -30% | -$1.25M |
|
|
OCRX
532
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $3.09M | ﹤0.01% |
238,152
| – | – |
|
|
QLTI
533
DELISTED
QLT Inc
QLTI
| $3.05M | ﹤0.01% |
548,164
+2,052
| +0.4% | +$10.2K |
|
534
Johnson & Johnson
JNJ
$640B
| $3.03M | ﹤0.01% |
33,065
-1,906
| -5% | -$176K |
|
535
Lindsay Corp
LNN
$1.14B
| $2.98M | ﹤0.01% |
35,972
-790
| -2% | -$61.5K |
|
536
Berkshire Hathaway Class B
BRK.B
$1.1T
| $2.95M | ﹤0.01% |
24,915
-643
| -3% | -$74.4K |
|
537
Quest Diagnostics
DGX
$26B
| $2.95M | ﹤0.01% |
+55,037
| New | +$3.26M |
|
538
Bloomin' Brands
BLMN
$754M
| $2.94M | ﹤0.01% |
122,594
-266,117
| -68% | -$6.42M |
|
539
Piper Sandler
PIPR
$4.99B
| $2.93M | ﹤0.01% |
296,260
-115,848
| -28% | -$1.06M |
|
540
Gyre Therapeutics
GYRE
$629M
| $2.89M | ﹤0.01% |
885
+3
| +0.3% | +$11.8K |
|
|
XNPT
541
DELISTED
XENOPORT, INC.
XNPT
| $2.82M | ﹤0.01% |
490,723
-374,816
| -43% | -$2.03M |
|
|
MXT
542
DELISTED
MAXCOM TELECOMUNICACIONES S A DE C V SPONSORED ADR REP (MX)
MXT
| $2.78M | ﹤0.01% |
1,706,000
| – | – |
|
543
Watts Water Technologies
WTS
$11.2B
| $2.72M | ﹤0.01% |
43,974
-733
| -2% | -$42.5K |
|
544
BioCryst Pharmaceuticals
BCRX
$2.42B
| $2.72M | ﹤0.01% |
357,352
-92,648
| -21% | -$587K |
|
545
MacroGenics
MGNX
$233M
| $2.71M | ﹤0.01% |
+98,606
| New | +$2.58M |
|
|
STML
546
DELISTED
Stemline Therapeutics, Inc.
STML
| $2.69M | ﹤0.01% |
+137,186
| New | +$3.66M |
|
|
RGLS
547
DELISTED
Regulus Therapeutics
RGLS
| $2.66M | ﹤0.01% |
2,995
+12
| +0.4% | +$10.3K |
|
|
INFN
548
DELISTED
Infinera Corporation Common Stock
INFN
| $2.65M | ﹤0.01% |
270,583
-703,823
| -72% | -$7M |
|
549
Ciena
CIEN
$46.8B
| $2.52M | ﹤0.01% |
105,346
+11,271
| +12% | +$268K |
|
550
Loews
L
$24.5B
| $2.49M | ﹤0.01% |
+51,601
| New | +$2.47M |
|
Similar funds
Jennison Associates's Q4 2013 Portfolio in Review
As of Q4 2013, Jennison Associates held 759 positions worth $102B, up 6.9% from $95.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q4 2013 filing shows 79 new, 184 increased, 411 reduced and 54 closed positions. Its largest new stake was Allergan plc: 2,016,619 shares worth $339M. The largest sale was UnitedHealth, an estimated $682M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q4 2013 buy was Allergan plc: 2,016,619 shares worth $339M.
- Jennison Associates added most to Bristol-Myers Squibb in Q4 2013, an estimated $734M increase.
- Jennison Associates's biggest Q4 2013 reduction was UnitedHealth, cutting an estimated $682M.
- Jennison Associates fully exited Perrigo in Q4 2013, selling an estimated $585M.
- Jennison Associates's ten largest holdings make up 20% of its $102B portfolio in Q4 2013.
- Jennison Associates opened 79 new positions and closed 54 in Q4 2013.
- Jennison Associates's portfolio value rose 6.9% quarter-over-quarter to $102B.
Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.